Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Constitutive Activation of Integrin α9 Augments Self-Directed Hyperplastic and Proinflammatory Properties of Fibroblast-like Synoviocytes of Rheumatoid Arthritis.
Emori T, Hirose J, Ise K, Yomoda JI, Kasahara M, Shinkuma T, Yoshitomi H, Ito H, Hashimoto M, Sugahara S, Fujita H, Yamamoto N, Morita Y, Narumiya S, Aramori I. Emori T, et al. Among authors: sugahara s. J Immunol. 2017 Nov 15;199(10):3427-3436. doi: 10.4049/jimmunol.1700941. Epub 2017 Oct 16. J Immunol. 2017. PMID: 29038247 Free PMC article.
Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Yamamoto S, et al. Among authors: sugahara s. Eur J Pharmacol. 2007 Mar 22;559(2-3):219-26. doi: 10.1016/j.ejphar.2006.11.079. Epub 2006 Dec 12. Eur J Pharmacol. 2007. PMID: 17250824
It inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha production in mice with an ED50 value of 2.1 mg/kg [Yamamoto, S., Sugahara, S., Naito, R., Ichikawa, A., Ikeda, K., Yamada, T., Shimizu, Y., 2006. ...
It inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha production in mice with an ED50 value of 2.1 mg/kg [Yamamoto, S …
Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
Shirasuna K, Koelsch G, Seidel-Dugan C, Salmeron A, Steiner P, Winston WM, Brodkin HR, Nirschl CJ, Abbott S, Kinugasa F, Sugahara S, Ohori M, Takeuchi M, Hicklin DJ, Yoshida T. Shirasuna K, et al. Among authors: sugahara s. Cancer Treat Res Commun. 2021;28:100433. doi: 10.1016/j.ctarc.2021.100433. Epub 2021 Jul 11. Cancer Treat Res Commun. 2021. PMID: 34273876 Free article.
Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models.
Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Yamamoto S, et al. Among authors: sugahara s. Eur J Pharmacol. 2006 Nov 21;550(1-3):166-72. doi: 10.1016/j.ejphar.2006.08.023. Epub 2006 Aug 30. Eur J Pharmacol. 2006. PMID: 17010967
YM-393059 is a novel phosphodiesterase (PDE) 7A and PDE4 dual inhibitor that inhibits both Th1 [interleukin (IL)-2 and interferon-gamma] and Th2 (IL-4) cytokines in vitro [Yamamoto, S., Sugahara, S., Naito, R., Ichikawa, A., Ikeda, K., Yamada, T., Shimizu, Y. …
YM-393059 is a novel phosphodiesterase (PDE) 7A and PDE4 dual inhibitor that inhibits both Th1 [interleukin (IL)-2 and interferon-gamma] and …
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment.
Thumkeo D, Punyawatthananukool S, Prasongtanakij S, Matsuura R, Arima K, Nie H, Yamamoto R, Aoyama N, Hamaguchi H, Sugahara S, Takeda S, Charoensawan V, Tanaka A, Sakaguchi S, Narumiya S. Thumkeo D, et al. Among authors: sugahara s. Cell Rep. 2022 Jun 7;39(10):110914. doi: 10.1016/j.celrep.2022.110914. Cell Rep. 2022. PMID: 35675777 Free article.
259 results